(4-(2-fluoroethoxy)phenyl)methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(2-fluoroethoxy)phenyl)methanamine
• 英文别名: 4-(2-Fluoro-ethoxy)-benzylamine；[4-(2-fluoroethoxy)phenyl]methanamine
• 化学式: C₉H₁₂FNO
• 分子量: 169.199
• InChiKey: GNAZDYQSJFCDJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-(2-fluoroethoxy)phenyl)methanamine 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 生成 C₂₂H₂₈F₂N₄O₂
  参考文献：
  名称：

  改善帕金森病的治疗：基于结构的新型 5-HT2A 受体拮抗剂/反向激动剂的开发

  摘要：

  Pimavanserin是FDA于2016年批准的选择性5-HT 2A受体拮抗剂和反向激动剂，用于治疗帕金森病精神病（PDP）患者。但匹马万色林具有潜在风险，会增加老年患者的死亡率，也会增加患者 QT 间期延长的风险。因此，迫切需要寻找高效、低毒的新药。基于匹马范色林的对接研究，设计合成了一系列新型匹马范色林衍生物（ 7-1∼7-37 ）。通过细胞试验评估了生物活性，化合物7 – 16的 5-HT 表现出高 50 倍2A受体拮抗剂活性（IC 50  = 0.54 vs 27.3 nM）和反向激动剂活性（IC 50  = 2.1 vs 50 nM）是匹马万色林的 23 倍。此外，7 - 16显示 5-HT2A 和 hERG 活性之间的效力窗口比匹马万色林增加。此外，化合物7-16表现出优异的体外和体内药代动力学，体内功能活性提高了4倍，并且具有良好的安全性。因此，化合物7 – 16代表了一种

  DOI：

  10.1016/j.ejmech.2022.114246
• 作为产物：
  描述：

  4-[[叔丁氧酰胺]甲基]-苯酚 在 盐酸 、 四正辛基溴化铵 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 14.0h， 生成 (4-(2-fluoroethoxy)phenyl)methanamine
  参考文献：
  名称：

  Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation

  摘要：

  The noninvasive imaging of MMP activity in vivo could have a high impact in basic research as well as in clinical applications. This approach can be established using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by means Of PET. However, the complexity of diseases associated with dysregulated MMP expression necessitates the imaging of distinct MMPs or MMP subgroups to distinguish their individual role in specific diseases. To this end, selective and potent MMP-13 inhibitors based on a N, N'-bis(benzyppyrimidine-4,6-dicarboxamide core have been synthesized and successfully radiolabeled with carbon-11, fluorine-18, and gallium-68. Selected radiolabeled candidates were evaluated in-vitro and in vivo regarding their pharmacokinetic properties and metabolic stability.

  DOI：

  10.1021/acs.jmedchem.6b01284

文献信息

• [EN] COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES<br/>[FR] COMPOSÉS, SELS CORRESPONDANTS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES
  申请人：ACADIA PHARM INC

  公开号：WO2019040107A1

  公开（公告）日：2019-02-28

  The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

  本公开涉及按照式（I）的化合物，用于治疗疾病。
• Compounds, salts thereof and methods for treatment of diseases
  申请人：ACADIA PHARMACEUTICALS INC.

  公开号：US11345693B2

  公开（公告）日：2022-05-31

  The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

  本公开涉及可用于治疗疾病的式 (I) 化合物。
• 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1805163B1

  公开（公告）日：2008-10-01
• COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES
  申请人：Acadia Pharmaceuticals Inc.

  公开号：EP3672954A1

  公开（公告）日：2020-07-01
• Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation
  作者：Verena Hugenberg、Stefan Wagner、Klaus Kopka、Michael Schäfers、Robert C. Schuit、Albert D. Windhorst、Sven Hermann

  DOI：10.1021/acs.jmedchem.6b01284

  日期：2017.1.12

  The noninvasive imaging of MMP activity in vivo could have a high impact in basic research as well as in clinical applications. This approach can be established using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by means Of PET. However, the complexity of diseases associated with dysregulated MMP expression necessitates the imaging of distinct MMPs or MMP subgroups to distinguish their individual role in specific diseases. To this end, selective and potent MMP-13 inhibitors based on a N, N'-bis(benzyppyrimidine-4,6-dicarboxamide core have been synthesized and successfully radiolabeled with carbon-11, fluorine-18, and gallium-68. Selected radiolabeled candidates were evaluated in-vitro and in vivo regarding their pharmacokinetic properties and metabolic stability.